Syndax Pharmaceuticals, Inc. (SNDX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 8, 2026 2:00 PM EDT
Company Participants
Michael Metzger – CEO & Director
Keith Goldan – CFO, Treasurer & Principal Accounting Officer
Conference Call Participants
Corinne Jenkins – Goldman Sachs Group, Inc., Research Division
Presentation
Corinne Jenkins
Goldman Sachs Group, Inc., Research Division
All right. Good afternoon, everyone, thanks again for joining us at the Goldman Sachs Global Healthcare Conference. We’re thrilled to have Michael Metzger; and Keith Goldan, Chief Executive and Chief Financial Officer for Syndax here with us this afternoon. And maybe we’ll just kick it off some high-level questions.
First, how do you think about the core competencies of Syndax. And how does that inform kind of your strategic priorities for the business over the near term?
Question-and-Answer Session
Michael Metzger
CEO & Director
First of all, thank you, Corrine for inviting us here today, great opportunity to be in front of this audience. So Syndax is in a great position as a company. You mentioned our core competencies. We’ve been able to bring two drugs all the way through development and get them approved and certainly launched them in the last year plus has been very successful for the company. That kind of informs our core competencies. I would highlight R&D and the ability to translate early science into products of meeting and bringing them all the way through development.
So the R&D capabilities of Syndax are quite strong, gotten more robust over time. So that is something we lean on significantly to advance our medicines and really differentiate in the marketplace. And then, of course, the commercialization competency within hem today, we think is differentiating for us as we’ve advanced both of our medicines and they’re both hem medicines to bring them to as many patients as possible. So
You must be logged in to post a comment Login